First-In-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients With Advanced Hepatocellular Carcinoma
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-12-2616
Full Text
Open PDFAbstract
Available in full text
Date
January 29, 2013
Authors
Publisher
American Association for Cancer Research (AACR)